Brought to you by 
Leading cancer centers launch Juno Therapeutics; company gets $120mm through Series A; later adds more
24 Apr 2014
Executive Summary
The Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute joined forces to launch Juno Therapeutics Inc., a company tasked with developing T cell-based cancer immunotherapies. Arch Venture Partners and the Alaska Permanent Fund (managed by Crestline Investors) are initial investors in the start-up’s concurrent $120mm Series A round.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Leading cancer centers launch Juno Therapeutics; company gets $120mm through Series A; later adds more
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice